Transplantation of Umbilical Cord-derived Mesenchymal Stem Cells Via Different Routes

Cerebral Palsy Clinical Trial

Official title:

Transplantation of Umbilical Cord-derived Mesenchymal Stem Cells Via Different Routes for the Treatment of Cerebral Palsy in Children

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03414697
• Other study ID #: FirstHospitalDalianMU004
• Status: Not yet recruiting
• Phase: N/A
• First received: January 22, 2018
• Last updated: January 26, 2018
• Start date: April 2018
• Est. completion date: December 2020

Study information

• Verified date: January 2018
• Source: The First Affiliated Hospital of Dalian Medical University
• Contact: Jing Liu, Ph.D
• Phone: 86041184394568
• Email: liujing.dlrmc[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To preliminarily evaluate the efficacy and safety of umbilical cord-derived mesenchymal stem cells (UC-MSCs), and compare the efficacy of UC-MSCs administered through the intravenous, intrathecal, and intranasal routes, in the treatment of cerebral palsy in children.

Description:

Cerebral palsy refers to a neurological disorder caused by a non-progressive brain injury or malformation that occurs in early childhood. It can result in central motor deficits, developmental retardation, abnormal posture, abnormal muscular strength, abnormal muscle tone and/or dysreflexia. It has a high disability rate. There is currently no effective treatment for cerebral palsy. Conventional treatments for cerebral palsy are often tiresome and expensive and have a slow onset of action. Stem cells have been recently used in the treatment of cerebral palsy. This provides a novel method for the treatment of cerebral palsy. According to the existing clinical studies, neural stem cells, bone marrow-derived mesenchymal stem cells, and umbilical cord-derived mesenchymal stem cells (UC-MSCs) are mainly used as the seed cells for the treatment of cerebral palsy. UC-MSCs are the most promising seed cells for the treatment of cerebral palsy because of the advantages including rich sources, ease of harvesting, short doubling time, low immunogenicity, long-time survival post-transplantation, and no ethical issues. UC-MSCs have been widely used to treat Parkinson's disease, rheumatoid arthritis, traumatic brain injury, aplastic anemia, and decompensated liver disease. However,only two studies, and performed only in China, are reported on the treatment of cerebral palsy with UC-MSCs. One from the Hospital 463 of PLA reported 51 patients with cerebral palsy whose symptoms had not been obviously improved after 1 year of rehabilitative treatment. These patients received intrathecal injection of UC-MSCs for three times, once a week, followed by one injection of UC-MSCs via the peripheral vein in the fourth week. Four UC-MSCs injections, once per week, were considered as one course of treatment. Activities of daily living scale score was compared between before and after treatment to evaluate efficacy. Another study is a case report from China. In this report, a combined intravenous and intrathecal injection of UC-MSCs was used to treat cerebral palsy in a 5-year-old child. 28-month follow-up results revealed that the child's gross motor function, immune function, muscle strength, and language ability improved and adverse reactions were not obvious.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 44
• Est. completion date: December 2020
• Est. primary completion date: September 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 18 Years

Eligibility

Inclusion Criteria:

• Patients diagnosed with hypoxic/ischemic cerebral palsy, primarily including birth asphyxia and premature children

• Patients with spastic quadriplegia

• Patients with moderate to severe cerebral palsy, GMFM scores of 2-3

• Age at 2-18 years

• Provision of signed informed consent by legal representatives of the child prior to start of the study

Exclusion Criteria:

• Those with systemic diseases that likely interfere with the treatment or child's compliance

• Those complicated by life-threatening diseases of any organ

• Those with brain deformity

• Those with uncontrolled epilepsy

• Those with abnormal behavior or mood disorders

• Those with allergies especially those who are allergic to blood products

• Those are infected with infectious diseases

• Those who had underwent a craniocerebral surgery in other clinical trials

Related Conditions & MeSH terms

• Cerebral Palsy

Intervention

Other:
• Control group
The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy.

Procedure:
• UC-MSCs
Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Dalian Medical University	Dalian	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Dalian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Gross Motor Function Measure (GMFM)-88 item score	a 4-point scale that is divided into five categories including lying and rolling, sitting, crawling and kneeling, standing, walking, running, and jumping. A score of 0 indicates that the child does not initiate the task; 1 indicates that the child initiates the task (completes < 10% of the activity); 2 indicates that the child partially completes the task (completes from 10 to 99% of the activity); 3 indicates that the child completes the task (100%). The sum of score of the five categories is used as the evaluation outcome.It is used to evaluate gross motor function.	12 months after 2 courses of treatment with UC-MSCs.
Secondary	Fine Motor Function Measure scale (FMFM) score	To evaluate fine motor function.The scale is divided into 45 items covering visual tracing (7 items), upper extremity range of motion (8 items), grab ability (8 items), operational ability (10 items), and hand-eye coordination (12 items). The FMFM is a 4-point scale with the score range of 0-3. The original total score is 135. The summed score for evaluating fine motor function measure is 0-100.	1, 3, 6, 9 and 12 months after 2 courses of treatment with UC-MSCs.
Secondary	The Modified Ashworth scale (MAS) score	To evaluate muscle tone. The MAS score is divided into six grades: 0, 1, 1+, 2, 3 and 4. Passive full ranges of motion exercises are performed by moving the knee and ankle until the patient feel a slight resistance from hamstrings and plantar flexor muscles (soleus muscle and gastrocnemius muscle). The average score is calculated across three repeated measurements.	1, 3, 6, 9 and 12 months after 2 courses of treatment with UC-MSCs.
Secondary	Gesell Development Schedule score	To evaluate neurobehavioral development.	1, 3, 6, 9 and 12 months after 2 courses of treatment with UC-MSCs.
Secondary	Incidence of adverse reactions	Liver and kidney dysfunction, fever, infection, vomiting.	1, 3, 6, 9 and 12 months after 2 courses of treatment with UC-MSCs.